TGF-β receptor type-1 (TGFBR1; ALK5; SKR4; TβR-I) inhibitors are reported in a recent Bisichem Co. Ltd. patent as potentially useful for the treatment of cancer, obesity, diabetes, fibrosis, autoimmune diseases and vascular disorders.
Genentech Inc. researchers have described phenol derivatives acting as probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α) and/or transcription activator BRG1 (SMARCA4; BAF190A; SNF2-β) degradation inducers reported to be useful for the treatment of cancer.
Research at Abbvie Inc. and Calico Life Sciences LLC has led to the development of proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to tyrosine-protein phosphatase non-receptor type 2 (PTPN2; TCPTP) and/or PTPN1B. They are reported to be useful for the treatment of cancer, type 2 diabetes and nonalcoholic steatohepatitis (NASH).
Cocrystal Pharma Inc., Merck Sharp & Dohme Corp. and MSD R&D (China) Co. Ltd. have jointly patented new cap-dependent endonuclease (CEN) (influenza virus) inhibitors that are reported to be useful for the treatment of influenza.
Research at Nimbus Saturn Inc. has led to the development of mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) inhibitors reported in a recent patent to be useful for the treatment of cancer.
Researchers at Flare Therapeutics Inc. have prepared and tested quinoline compounds acting as peroxisome-proliferator receptor γ (PPARγ) inverse agonists reported to be useful for the treatment of bladder cancer.
Indole derivative compounds acting as ferroptosis inhibitors have been reported in a Mitoimmune Therapeutics Inc. patent as potentially useful for the treatment of neurodegeneration, diabetes, stroke, myocardial infarction, liver, lung diseases, eye, renal disorders, among others.
Eurofarma Laboratórios SA and Universidade Federal do Rio de Janeiro have patented N-acylhydrazone compounds acting as sodium channel protein type 9 subunit α (SCN9A; Nav1.7) and/or SCN10A (Nav1.8) blockers which are described as being potentially useful for the treatment of pain.
RSS